|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
CA2157577C
(en)
|
1993-03-19 |
2009-11-17 |
Se-Jin Lee |
Growth differentiation factor-8
|
|
ES2330062T3
(es)
|
1998-05-06 |
2009-12-03 |
Metamorphix, Inc. |
Procedimientos para tratar la diabetes por inhibicion de gdf-8.
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
EE200200025A
(et)
|
1999-07-20 |
2003-04-15 |
Pharmexa A/S |
Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
|
|
US6670140B2
(en)
|
2001-03-06 |
2003-12-30 |
The Procter & Gamble Company |
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
WO2004108157A2
(en)
|
2003-06-02 |
2004-12-16 |
Wyeth |
Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
|
|
WO2005066204A2
(en)
|
2003-12-31 |
2005-07-21 |
Schering-Plough Ltd. |
Neutralizing epitope-based growth enhancing vaccine
|
|
CA2558478A1
(en)
|
2004-03-02 |
2005-09-15 |
Acceleron Pharma Inc. |
Alk7 and myostatin inhibitors and uses thereof
|
|
US20070178095A1
(en)
|
2004-03-23 |
2007-08-02 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
MX2007000976A
(es)
|
2004-08-12 |
2007-04-10 |
Wyeth Corp |
Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
TW200724548A
(en)
|
2005-04-25 |
2007-07-01 |
Pfizer |
Antibodies to myostatin
|
|
CN101198624B
(zh)
|
2005-05-06 |
2012-10-10 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
|
EP1773041A1
(en)
|
2005-07-21 |
2007-04-11 |
Chao-Hung Wu |
Audio/video data transmission system using the internet to interconnect telephones
|
|
US7888486B2
(en)
|
2005-08-19 |
2011-02-15 |
Wyeth Llc |
Antagonist antibodies against GDF-8
|
|
KR101135220B1
(ko)
|
2005-10-06 |
2012-04-24 |
일라이 릴리 앤드 캄파니 |
항-마이오스타틴 항체
|
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
US20070149458A1
(en)
|
2005-12-06 |
2007-06-28 |
Amgen Inc. |
Uses of myostatin antagonists
|
|
WO2007109686A2
(en)
|
2006-03-20 |
2007-09-27 |
University Of Pittsburgh |
Immunomodulation of inflammatory conditions utilizing follistatin-like protein-1 and agents that bind thereto
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
BRPI0715072A2
(pt)
|
2006-08-03 |
2013-06-25 |
Orico Ltd |
antagonistas de miostatina
|
|
HRP20130320T1
(en)
|
2006-09-05 |
2013-05-31 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
PL2207775T3
(pl)
|
2007-11-05 |
2012-08-31 |
Novartis Ag |
Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
|
|
DK3750552T5
(da)
|
2008-08-14 |
2024-08-26 |
Acceleron Pharma Inc |
Gdf-fælder
|
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
|
AU2010204985A1
(en)
*
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
ES2655877T3
(es)
|
2009-04-27 |
2018-02-22 |
Novartis Ag |
Composiciones y métodos para aumentar el crecimiento muscular
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
|
PH12013500315A1
(en)
|
2010-08-16 |
2013-04-29 |
Amgen Inc |
Antibodies that bind myostatin, compositions and methods
|
|
CA2817008A1
(en)
|
2010-11-08 |
2012-05-18 |
Acceleron Pharma Inc. |
Actriia binding agents and uses thereof
|
|
SMT201800092T1
(it)
|
2011-11-14 |
2018-03-08 |
Regeneron Pharma |
Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
MY177331A
(en)
|
2012-06-15 |
2020-09-12 |
Pfizer |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
KR20150136061A
(ko)
|
2013-02-01 |
2015-12-04 |
산타 마리아 바이오테라퓨틱스, 인코포레이티드 |
대상에 항-액티빈-a 화합물의 투여
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
WO2015022658A2
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
WO2016168613A1
(en)
*
|
2015-04-15 |
2016-10-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of increasing strength and functionality with gdf8 inhibitors
|
|
US20180008672A1
(en)
|
2016-07-08 |
2018-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
|